Epimacular Brachytherapy for Previously Treated Neovascular Age-Related Macular Degeneration (MERLOT)

Abstract

These results do not support the use of EMB for chronic, active, neovascular AMD. Safety is acceptable out to 12 months, but radiation retinopathy can occur later, so further follow-up is planned.